By Biomarker Scientist Niccolo Fuin Lots of biological motivation on AD progression and molecular biomarkers. Most interesting session for me was: “Development Of New Models And Analysis Methods: Novel Imaging Analysis“ in which Pablo F.
Transfer learning for brain segmentation Pre-task selection and data limitations
Actigraphic Monitoring of Sleep-Wake Cycle in Schizophrenia Outpatients
Receiving a Long-Acting Injectable Antipsychotic: Feasibility and Initial
Results From a Prospective RCT
The COVID-19 pandemic has put considerable strain on the healthcare services across the globe and is impacting clinical development across many therapeutic areas, as many resources are being diverted to fighting the pandemic.
The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer’s disease. AMYPAD PNHS adds (semi-)quantitative amyloid PET imaging to several European parent cohorts to predict AD-related progression as well as address methodological challenges in amyloid PET.
On the performance of manually or automatically segmented DATSCAN-SPECT for biomarker extraction in PD
81-88 of 162 results